Lupin announced that it has launched its generic cyanocobalamin nasal spray for the prevention and treatment of vitamin B12 deficiency in the US. The FDA approved the company’s ANDA for the 500 mcg/spray intranasal cyanocobalamin in June 2023.
The Lupin cyanocobalamin nasal spray is a generic of Par Pharmaceutical’s Nascobal nasal spray, which was approved by the FDA in 2004. Lupin originally submitted its ANDA in 2017, and Par parent company ENDO initiated patent litigation in response.
Read the Lupin press release.
